Gleiss Lutz advises shareholders of WESSLING Group on sale of their shares to ALS

Gleiss Lutz has advised the shareholders of WESSLING Holding GmbH & Co. KG (Altenberge) on the sale of all the shares in the company to ALS Limited, an Australian company.

The WESSLING Group is a major European provider of laboratory analytics, consulting and engineering services. Founded in 1983 and owner-managed since then, the Group provides environmental, food and pharmaceutical services, employing around 1,200 staff at 22 locations in Europe. In 2023, the Group generated turnover of approx. EUR 98 million.

ALS is a global leader in laboratory and testing services, with over 18,000 employees at 350 locations in more than 65 countries, offering comprehensive testing solutions to clients in a wide range of industries all over the world. ALS is listed on the Australian Securities Exchange in Sydney.

Closing remains subject to regulatory approvals and clearances.

The following Gleiss Lutz team headed by Dr. Thomas Menke (partner, lead) and Dr. Fabian Mumme (both M&A, both Düsseldorf) advised the Wessling family on this transaction: Dr. Johann Wagner (partner), Dr. Philipp Niemann (both Tax, both Hamburg), Dr. Steffen Krieger (partner), Dr. Florian Wieg (both Employment), Dr. Jacob von Andreae (partner), Aylin Hoffs (both Public Law), Dr. Martin Raible (partner), Antonia Harbusch (Merger Control), Kai Zimutta, Dr. Philipp Lucks, Thomas Baldzuhn (all M&A, all Düsseldorf).